Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Janssen Says In Vitro Studies Suggest Tremfya Neutralizes Il-23 Where It Is Produced

New Data Show Tremfya® (gGuselkumab) Binds To Both Inflammatory Cells And Interleukin (II)-23, Supporting A Hypothesis For A Differentiated Mechanism From Risankizumab
byBenzinga Newsdesk
May 18, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

New Data Show Tremfya® (gGuselkumab) Binds To Both Inflammatory Cells And Interleukin (II)-23, Supporting A Hypothesis For A Differentiated Mechanism From Risankizumab

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0